Pfizer to invest $120M in Kalamazoo facility expansion

267
Gov. Gretchen Whitmer spoke during Pfizer's announcement to invest $120 million in the production of oral treatment for COVID-19. Courtesy Pfizer

Pfizer will invest $120 million into its existing Kalamazoo facility to support the production of an oral treatment for COVID-19.

Pfizer joined Gov. Gretchen Whitmer on Monday, June 6, in announcing it will invest $120 million at its 1,300-acre Pfizer Global Supply facility at 7000 Portage Road in Kalamazoo.

The expansion will support expanded production of Pfizer’s COVID-19 oral treatment PAXLOVID and will result in the creation of more than 250 high-skilled jobs.

Whitmer said this investment will grow Michigan’s economy.

“Pfizer’s $120 million expansion in Kalamazoo, creating 250 good-paying jobs making PAXLOVID, will save lives and build on Michigan’s economic momentum,” she said. “Pfizer’s Kalamazoo facility also made some of the first doses of the vaccine, and now this proud Michigan company will play a critical role in both the treatment and prevention of COVID.”

Pfizer said this investment is another step in the company’s effort to bring more biopharmaceutical manufacturing to the U.S., increasing its capability to produce and supply treatments and medicines for patients in the U.S. and around the world.

“Pfizer Global Supply has made the impossible possible, making billions of vaccine doses and now millions of treatment courses to help battle the deadly COVID-19 pandemic,” said Albert Bourla, chair and CEO of Pfizer. “By increasing production at our Michigan facility, we are both helping patients around the world and expanding important manufacturing innovation to the U.S. This investment builds upon our $5 billion of investments across our manufacturing and distribution portfolio since 2017 to support the ongoing growth of U.S. manufacturing leadership.”

To date, Pfizer has manufactured over 5.5 million packs of PAXLOVID globally across 26 countries, including 1.3 million courses shipped to the U.S. The new investment will allow Pfizer to increase supply capacity for PAXLOVID as needed to help meet global demand. The company said the move makes the city of Kalamazoo among the world’s largest producers of active pharmaceutical ingredient (API), with the capacity to produce 1,200 metric tons annually.

Pfizer also plans to expand its modular aseptic processing (MAP) sterile injectable pharmaceutical production facility in Kalamazoo with a phase-two investment. The expansion adds to the initial investment of $450 million in phase one to build a 400,000-square-foot production facility.

“Pfizer’s Kalamazoo facility has been at the forefront of pharmaceutical manufacturing for more than 135 years through the legacy company Upjohn,” said Mike McDermott, chief global supply officer, Pfizer.

“The Kalamazoo facility uses some of our most innovative manufacturing technology and has been essential in Pfizer’s fight against COVID-19, producing more than 1 billion doses of COVID-19 vaccine at the site to date. Through this expansion, we will continue to invest in the next generation of manufacturing and supply chain resilience.”

Facebook Comments